Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – menin inhibitors face off again
Kura will see more combo data, while a new contender from Sumitomo emerges.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
Triple meeting 2024 – Tyra’s targeted FGFR3 push
The company reckons it’s got what it takes to hit the right member of the FGFR family.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
